CME/CE

Use the tool below to view all available Prova Series

Taking Action Against RSV: No Child Unprotected
Taking Action Against RSV: No Child Unprotected
CME/CE
Taking Action Against RSV: No Child Unprotected
0.50 credits
- Tina Q. Tan, MD
- Yvonne Maldonado, MD
0.50 credits
MOA: CDH6-Targeted Antibody-Drug Conjugates
MOA: CDH6-Targeted Antibody-Drug Conjugates
MinuteCE®
MOA: CDH6-Targeted Antibody-Drug Conjugates
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
0.50 credits 5 episodes
- Kathleen Moore, MD, MS
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
CME/CE
Treating MASH With Compensated Cirrhosis: A Serious Unmet Need
0.25 credits
- Naim Alkhouri, MD, FAASLD, DABOM
0.25 credits
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
MinuteCE®
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
MinuteCE®
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
Data Dive: Clinical Evidence Behind CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
MinuteCE®
Data Dive: Clinical Evidence Behind CELMoDs
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Safety First: Navigating CELMoD-Associated Toxicities
Safety First: Navigating CELMoD-Associated Toxicities
MinuteCE®
Safety First: Navigating CELMoD-Associated Toxicities
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Mastering the Sequence: CELMoDs Across Treatment Lines
Mastering the Sequence: CELMoDs Across Treatment Lines
MinuteCE®
Mastering the Sequence: CELMoDs Across Treatment Lines
1.00 program credit
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 program credit
 Real-World Ready: Practical Tips for Community Oncologists
 Real-World Ready: Practical Tips for Community Oncologists
MinuteCE®
 Real-World Ready: Practical Tips for Community Oncologists
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit

CME/CE

Popular

Title

Share on ReachMD